Category: skin disease

June 16, 2023 / Clin Cancer Res

  • Pich-Bavastro C, Yerly L, Di Domizio J, Tissot-Renaud S, Gilliet M, Kuonen F
Purpose: Cemiplimab is approved for the treatment of locally advanced basal cell carcinomas (BCCs), however with mitigated results. We sought to interrogate the cellular and molecular transcriptional reprogramming underlying BCC…
May 30, 2023 / Cells

  • Izraely S, Ben-Menachem S, Malka S, Sagi-Assif O, Bustos MA, Adir O, Meshel T, Chelladurai M, Ryu S, Ramos RI, Pasmanik-Chor M, Hoon DSB, Witz IP
Previous studies from our lab demonstrated that the crosstalk between brain-metastasizing melanoma cells and microglia, the macrophage-like cells of the central nervous system, fuels progression to metastasis. In the present…
March 8, 2023 / Eur Urol

  • Hannan R, Mark F. McLaughlin, Laurentiu M. Pop, Ivan Pedrosa, Payal Kapur, Aurelie Garant, Chul Ahn, Alana Christie, James Zhu, Tao Wang, Liliana Robles, Deniz Durakoglugil, Solomon Woldu, Vitaly Margulis, Jeffrey Gahan, James Brugarolas, Robert Timmerman, Jeffrey Cadeddu
Background: Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective…
March 3, 2023 / J Invest Dermatol

  • Chagani S, De Macedo MP, Carapeto F, Wang F, Marzese DM, Wani K, Haydu LE, Peng W, Ong GT, Warren SE, Beechem JM, Hoon DSB, Mills GB, Tetzlaff MT, Lazar AJ, Kwong LN, Davies MA
Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed…
February 27, 2023 / Transl Med Commun

  • Baranda JC, Mohyuddin GR, Bur AM, Shnayder Y, Sweeney KR, Kakarala K, Prouty M, Pathak H, Puri R, Mitra A, Madan R, Forrest ML, Huang A, Weir S, Godwin AK, Alhakamy NA, Griffin JD, Berkland CJ
Background: This window of opportunity trial evaluated the safety of intratumoral Copaxone® and profiled immune markers in biopsies before and after treatment. Methods: Patients with percutaneously accessible malignancies scheduled for…
November 11, 2022 / Sci Immunol

  • Whitley SK, Li M, Kashem SW, Hirai T, Igyártó BZ, Knizner K, Ho J, Ferris LK, Weaver CT, Cua DJ, McGeachy MJ, Kaplan DH
September 16, 2022 / J Invest Dermatol

  • Macchiarella G, Cornacchione V, Cojean C, Riker J, Wang Y, Te H, Ceci M, Gudjonsson JE, Gaulis S, Goetschy JF, Wollschlegel A, Gass SK, Oetliker-Contin S, Wettstein-Ling B, Schaefer DJ, Meschberger P, de Roche R, Osinga R, Wieczorek G, Naumann U, Lehmann JCU, Schubart A, Hofmann A, Roth L, Florencia EF, Loesche C, Traggiai E, Avrameas A, Prens EP, Röhn TA, Roediger B
August 15, 2022 / Front Immunol

  • Therien AD, Beasley GM, Rhodin KE, Farrow NE, Tyler DS, Boczkowski D, Al-Rohil RN, Holl EK, Nair SK
July 14, 2022 / Cancer Cell

  • van Krimpe An, Vivian I.V. Gerretsen, Evalyn E.A.P. Mulder, Mandy van Gulijk, Thierry P.P. van den Bosch, Jan von der Thüsen, Dirk J. Grünhagen, Cornelis Verhoef, Dana Mustafa, Joachim G. Aerts, Ralph Stadhouders, Floris Dammeijer
June 2, 2022 / Cancer Discov

  • Nirmal AJ, Maliga Z, Vallius T...Murphy GF, Santagata S, Sorger PK
January 10, 2022 / Nat Commun

  • Theocharidis G, Thomas BE, Sarkar D...Bhasin SS, Veves A, Bhasin M
December 2, 2021 / PLoS One

  • Leleux JA, Albershardt TC, Reeves R, James R, Krull J, Parsons AJ, ter Meulen J, Berglund P